An Open Label Phase I Study Evaluating Safety, Tolerability and Pharmacokinetics of SL-11047 in Patients With Refractory Lymphoma.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2016
At a glance
- Drugs PG 11047 (Primary)
- Indications Burkitt's lymphoma; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma
- Focus Adverse reactions
- Sponsors Progen Pharmaceuticals Limited
- 29 Jun 2016 Last checked against ClinicalTrials.gov record.
- 17 Sep 2008 Status changed from recruiting to completed, according to ClinicalTrialsl.gov.
- 08 Aug 2006 New trial record.